MAP2K7 and colonic neoplasm: ISG15 is upregulated following trametinib treatment in colon cancer cells and suppresses the anticancer effect of trametinib, suggesting combined targeting of ISG15 and mitogen-activated protein kinase kinase (MEK) as a promising therapeutic strategy for colon cancer treatment221.